or
Remember me
Back
1606 Corporation (CBDW) recently announced a 5% LOI stake in Adnexus Biotechnologies
In a landmark development that promises to transform the future of medical research and treatment, Adnexus Biotechnologies and Sanctum Therapeutics have announced a strategic merger aimed at revolutionizing the way we combat HIV and other infectious diseases. This fusion of cutting-edge artificial intelligence (AI)-driven drug discovery with breakthrough therapeutic innovations marks a pivotal moment in the ongoing battle against some of the world’s most persistent and deadly diseases.
Together, the combined entity stands poised to accelerate the development of life-saving therapies that have the potential to change the lives of millions of people globally. The merger not only signals a significant advancement in the fight against HIV but also showcases the power of technological innovation in advancing global healthcare.
Receive investor kits and email updates from Stockhouse and directly from these companies.